BSE:524506

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Coral Laboratories Limited manufactures and sells pharmaceutical formulations in India, Ethopia, and internationally. More Details


Snowflake Analysis

Flawless balance sheet and good value.

Share Price & News

How has Coral Laboratories's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 524506 is not significantly more volatile than the rest of Indian stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: 524506's weekly volatility (7%) has been stable over the past year.


Market Performance


7 Day Return

-7.2%

524506

0.3%

IN Pharmaceuticals

2.3%

IN Market


1 Year Return

83.0%

524506

45.3%

IN Pharmaceuticals

7.4%

IN Market

Return vs Industry: 524506 exceeded the Indian Pharmaceuticals industry which returned 45.3% over the past year.

Return vs Market: 524506 exceeded the Indian Market which returned 7.4% over the past year.


Shareholder returns

524506IndustryMarket
7 Day-7.2%0.3%2.3%
30 Day-17.0%0.3%8.1%
90 Day2.9%0.8%10.0%
1 Year83.0%83.0%47.0%45.3%9.4%7.4%
3 Year-65.5%-66.0%35.4%32.1%5.2%0.1%
5 Year-40.9%-42.1%9.3%5.5%52.4%41.0%

Long-Term Price Volatility Vs. Market

How volatile is Coral Laboratories's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Coral Laboratories undervalued compared to its fair value and its price relative to the market?

9.5%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: 524506 (₹312) is trading below our estimate of fair value (₹344.61)

Significantly Below Fair Value: 524506 is trading below fair value, but not by a significant amount.


Price To Earnings Ratio

PE vs Industry: 524506 is good value based on its PE Ratio (8.6x) compared to the IN Pharmaceuticals industry average (22.2x).

PE vs Market: 524506 is good value based on its PE Ratio (8.6x) compared to the Indian market (17.1x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 524506's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 524506 is good value based on its PB Ratio (0.9x) compared to the IN Pharmaceuticals industry average (2.1x).


Next Steps

Future Growth

How is Coral Laboratories forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

21.9%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Coral Laboratories has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Coral Laboratories performed over the past 5 years?

-10.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 524506 has high quality earnings.

Growing Profit Margin: 524506's current net profit margins (16%) are higher than last year (4.6%).


Past Earnings Growth Analysis

Earnings Trend: 524506's earnings have declined by 10.1% per year over the past 5 years.

Accelerating Growth: 524506's earnings growth over the past year (289.3%) exceeds its 5-year average (-10.1% per year).

Earnings vs Industry: 524506 earnings growth over the past year (289.3%) exceeded the Pharmaceuticals industry 22.9%.


Return on Equity

High ROE: 524506's Return on Equity (9.9%) is considered low.


Next Steps

Financial Health

How is Coral Laboratories's financial position?


Financial Position Analysis

Short Term Liabilities: 524506's short term assets (₹1.0B) exceed its short term liabilities (₹231.6M).

Long Term Liabilities: 524506's short term assets (₹1.0B) exceed its long term liabilities (₹32.5M).


Debt to Equity History and Analysis

Debt Level: 524506's debt to equity ratio (1.5%) is considered satisfactory.

Reducing Debt: 524506's debt to equity ratio has reduced from 4.6% to 1.5% over the past 5 years.

Debt Coverage: 524506's debt is well covered by operating cash flow (434.2%).

Interest Coverage: 524506 earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet


Next Steps

Dividend

What is Coral Laboratories's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 524506's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 524506's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 524506's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 524506's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: 524506 is not paying a notable dividend for the Indian market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 524506's dividend in 3 years as they are not forecast to pay a notable one for the Indian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.5yrs

Average board tenure


CEO

Girish Dhameja (39 yo)

no data

Tenure

₹2,090,989

Compensation

Mr. Girish Madanlal Dhameja has been an Whole-Time Director of Coral Laboratories Limited since May 26, 2017. His present profile includes handling export enquiry finalization and execution of order, busin...


CEO Compensation Analysis

Compensation vs Market: Girish's total compensation ($USD28.16K) is below average for companies of similar size in the Indian market ($USD51.27K).

Compensation vs Earnings: Girish's compensation has been consistent with company performance over the past year.


Board Members

NamePositionTenureCompensationOwnership
Girish Dhameja
Whole-Time Directorno data₹2.09mno data
Sushma Kadkade
CFO & Non-Executive Director3.5yrs₹1.26mno data
Sheela Kamdar
Non-Executive Independent Director6.17yrs₹43.00kno data
Sanket Mehta
Non-Executive Independent Director3.5yrs₹40.00kno data
Purvi Doshi
Additional Non-Executive Director1.5yrsno datano data
Saurabh Shah
Additional Independent Director1.5yrs₹15.00kno data

3.5yrs

Average Tenure

43yo

Average Age

Experienced Board: 524506's board of directors are considered experienced (3.5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Coral Laboratories Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Coral Laboratories Limited
  • Ticker: 524506
  • Exchange: BSE
  • Founded: 1994
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: ₹1.115b
  • Shares outstanding: 3.57m
  • Website: https://corallab.com

Number of Employees


Location

  • Coral Laboratories Limited
  • #3B, Patanwala Industrial Estate
  • Opp. Shreyas Cinema
  • Mumbai
  • Maharashtra
  • 400086
  • India

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
524506BSE (Mumbai Stock Exchange)YesEquity SharesININRAug 1998

Biography

Coral Laboratories Limited manufactures and sells pharmaceutical formulations in India, Ethopia, and internationally. The company offers antibiotics/antibacterial products, including antifungal, antiemetic...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/11/24 04:16
End of Day Share Price2020/11/23 00:00
Earnings2020/09/30
Annual Earnings2020/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.